MedPath

Effect of Substitution of Methadone by Buprenorphine on Gonadal Hormones and Seme

Not Applicable
Conditions
Male infertility in opioid substitution treatment.
Male infertility
Registration Number
IRCT2016011626040N1
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
40
Inclusion Criteria

men between 18 to 50 y/o; at least 6 months on Opioid Substitution Treatment & 3 months from last illegal opioid use; daily Methadone dose less than 60 mg/d; certification of therapist physician on stability & readiness of client for shifting from methadone to buprenorphine; diagnosis of methadone as the most important factor for undesirable hormonal & seminal analysis; written & signed informed consent form.
Exclusion criteria: evidence or signs of laps & relapse in buprenorphine treatment even with appropriate dose; absence from treatment more than 2 consecutive or 3 undulant weeks; absence from screening opioid urine test more than 2 consecutive or 3 undulant sessions; absence from hormonal & seminal analysis more than 2 weeks after appointed time; intolerance of methadone dose reduction for shifting to buprenorphine; intolerance of buprenorphine side effects.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath